BR112017002498A2 - derivados de 6-alquil-piridina como miméticos de smac - Google Patents
derivados de 6-alquil-piridina como miméticos de smacInfo
- Publication number
- BR112017002498A2 BR112017002498A2 BR112017002498A BR112017002498A BR112017002498A2 BR 112017002498 A2 BR112017002498 A2 BR 112017002498A2 BR 112017002498 A BR112017002498 A BR 112017002498A BR 112017002498 A BR112017002498 A BR 112017002498A BR 112017002498 A2 BR112017002498 A2 BR 112017002498A2
- Authority
- BR
- Brazil
- Prior art keywords
- smac mimetics
- pyridine derivatives
- alkyl pyridine
- smac
- mimetics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção refere-se à 6-alquinil-piridina de fórmula geral (i) (i) seu uso como miméticos de smac, composições farmacêutica contendo-as, e seu uso como medicamentos para o tratamento e/ou prevenção de doenças caracterizadas por proliferação excessiva ou anormal de célula e condições associadas, tal como câncer. os grupos r1 a r4 têm os significados fornecidos nas reivindicações e na especificação.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180554 | 2014-08-11 | ||
| EP14180554.9 | 2014-08-11 | ||
| PCT/EP2015/068349 WO2016023858A1 (en) | 2014-08-11 | 2015-08-10 | 6-alkynyl-pyridine derivatives as smac mimetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017002498A2 true BR112017002498A2 (pt) | 2017-12-05 |
| BR112017002498B1 BR112017002498B1 (pt) | 2022-10-11 |
Family
ID=51300621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017002498-5A BR112017002498B1 (pt) | 2014-08-11 | 2015-08-10 | Derivados de 6-alquil-piridina, preparação farmacêutica e uso |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US9481673B2 (pt) |
| EP (1) | EP3180339B1 (pt) |
| JP (1) | JP6250226B2 (pt) |
| KR (1) | KR102445744B1 (pt) |
| CN (2) | CN111440164B (pt) |
| AP (1) | AP2017009718A0 (pt) |
| AR (1) | AR101479A1 (pt) |
| AU (1) | AU2015303308B2 (pt) |
| BR (1) | BR112017002498B1 (pt) |
| CA (1) | CA2956123C (pt) |
| CL (1) | CL2017000326A1 (pt) |
| CO (1) | CO2017001226A2 (pt) |
| CY (1) | CY1121273T1 (pt) |
| DK (1) | DK3180339T3 (pt) |
| EA (1) | EA031424B1 (pt) |
| ES (1) | ES2711763T3 (pt) |
| HR (1) | HRP20190336T1 (pt) |
| HU (1) | HUE043915T2 (pt) |
| IL (1) | IL249844B (pt) |
| LT (1) | LT3180339T (pt) |
| ME (1) | ME03303B (pt) |
| MX (1) | MX2017001835A (pt) |
| NZ (1) | NZ728073A (pt) |
| PE (1) | PE20170193A1 (pt) |
| PH (1) | PH12017500231A1 (pt) |
| PL (1) | PL3180339T3 (pt) |
| PT (1) | PT3180339T (pt) |
| RS (1) | RS58355B1 (pt) |
| SG (1) | SG11201700999YA (pt) |
| SI (1) | SI3180339T1 (pt) |
| TR (1) | TR201902023T4 (pt) |
| TW (1) | TWI723959B (pt) |
| UA (1) | UA118887C2 (pt) |
| WO (1) | WO2016023858A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101479A1 (es) * | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
| EA038950B1 (ru) | 2016-05-19 | 2021-11-12 | Бёрингер Ингельхайм Интернациональ Гмбх | Способ получения производных 6-алкинил-пиридина |
| MX2019011572A (es) * | 2017-03-31 | 2019-11-18 | Boehringer Ingelheim Int | Tratamiento conjunto antineoplasico. |
| CN113453678A (zh) | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| TW202043466A (zh) | 2019-01-25 | 2020-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| MX2022003628A (es) | 2019-09-25 | 2022-07-21 | Debiopharm Int Sa | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. |
| CA3185332A1 (en) | 2020-06-03 | 2021-12-09 | Boehringer Ingelheim International Gmbh | Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein |
| WO2024175554A1 (en) | 2023-02-21 | 2024-08-29 | Institut Curie | Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060234360A1 (en) | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
| MX2007015419A (es) | 2005-06-08 | 2008-02-21 | Novartis Ag | Compuestos organicos. |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| BRPI0720049A2 (pt) * | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| US8859541B2 (en) * | 2012-02-27 | 2014-10-14 | Boehringer Ingelheim International Gmbh | 6-alkynylpyridines |
| US9249151B2 (en) | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
| US9278978B2 (en) | 2013-08-23 | 2016-03-08 | Boehringer Ingelheim International Gmbh | 6-Alkynyl Pyridine |
| AR101479A1 (es) * | 2014-08-11 | 2016-12-21 | Boehringer Ingelheim Int | Derivados de 6-alquinil-piridina |
-
2015
- 2015-08-07 AR ARP150102551A patent/AR101479A1/es unknown
- 2015-08-10 HU HUE15747820A patent/HUE043915T2/hu unknown
- 2015-08-10 EA EA201790349A patent/EA031424B1/ru not_active IP Right Cessation
- 2015-08-10 PE PE2017000209A patent/PE20170193A1/es unknown
- 2015-08-10 PL PL15747820T patent/PL3180339T3/pl unknown
- 2015-08-10 KR KR1020177005822A patent/KR102445744B1/ko active IP Right Grant
- 2015-08-10 SI SI201530611T patent/SI3180339T1/sl unknown
- 2015-08-10 US US14/821,870 patent/US9481673B2/en active Active
- 2015-08-10 MX MX2017001835A patent/MX2017001835A/es active IP Right Grant
- 2015-08-10 AP AP2017009718A patent/AP2017009718A0/en unknown
- 2015-08-10 JP JP2017507775A patent/JP6250226B2/ja active Active
- 2015-08-10 CA CA2956123A patent/CA2956123C/en active Active
- 2015-08-10 AU AU2015303308A patent/AU2015303308B2/en active Active
- 2015-08-10 SG SG11201700999YA patent/SG11201700999YA/en unknown
- 2015-08-10 CN CN201911357061.2A patent/CN111440164B/zh active Active
- 2015-08-10 CN CN201580039248.1A patent/CN106573930B/zh active Active
- 2015-08-10 ME MEP-2019-29A patent/ME03303B/me unknown
- 2015-08-10 DK DK15747820.7T patent/DK3180339T3/en active
- 2015-08-10 EP EP15747820.7A patent/EP3180339B1/en active Active
- 2015-08-10 TR TR2019/02023T patent/TR201902023T4/tr unknown
- 2015-08-10 BR BR112017002498-5A patent/BR112017002498B1/pt active IP Right Grant
- 2015-08-10 RS RS20190219A patent/RS58355B1/sr unknown
- 2015-08-10 NZ NZ728073A patent/NZ728073A/en unknown
- 2015-08-10 PT PT15747820T patent/PT3180339T/pt unknown
- 2015-08-10 ES ES15747820T patent/ES2711763T3/es active Active
- 2015-08-10 TW TW104125989A patent/TWI723959B/zh active
- 2015-08-10 LT LTEP15747820.7T patent/LT3180339T/lt unknown
- 2015-08-10 WO PCT/EP2015/068349 patent/WO2016023858A1/en active Application Filing
- 2015-10-08 UA UAA201702213A patent/UA118887C2/uk unknown
-
2016
- 2016-10-03 US US15/283,494 patent/US9801871B2/en active Active
- 2016-12-29 IL IL249844A patent/IL249844B/en active IP Right Grant
-
2017
- 2017-02-08 CL CL2017000326A patent/CL2017000326A1/es unknown
- 2017-02-08 CO CONC2017/0001226A patent/CO2017001226A2/es unknown
- 2017-02-08 PH PH12017500231A patent/PH12017500231A1/en unknown
- 2017-09-26 US US15/715,351 patent/US10413536B2/en active Active
-
2019
- 2019-02-19 CY CY20191100213T patent/CY1121273T1/el unknown
- 2019-02-20 HR HRP20190336TT patent/HRP20190336T1/hr unknown
- 2019-08-02 US US16/530,084 patent/US20190358218A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017002498A2 (pt) | derivados de 6-alquil-piridina como miméticos de smac | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| ECSP14018375A (es) | 6-alquinilo piridinas como miméticos smac | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| UY35711A (es) | Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
| UY35710A (es) | 6-alquinilpiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac | |
| BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| ECSP18049420A (es) | Composiciones novedosas, usos y métodos para hacerlas | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| BR112017003346B8 (pt) | Derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
| DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| BR112015009460A2 (pt) | compostos 2-cefem substituídos | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| BR112015030774A2 (pt) | novos compostos para o tratamento de câncer | |
| BR112017001803A2 (pt) | aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos | |
| BR112018008076A2 (pt) | derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos | |
| BR112017012007A2 (pt) | compostos orgânicos | |
| BR112017013031A2 (pt) | derivados de imidazopiridazina ligados à heterociclila como inibidores de pi3kbeta | |
| UY33877A (es) | Derivados de 5-alquinil-piridinas con efecto inhibitorio sobre la actividad de pi3k-alfa | |
| BR112017003881A2 (pt) | derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak | |
| NI201500172A (es) | Composiciones farmacéuticas | |
| BR112017025270A2 (pt) | composto, composição farmacêutica, e, medicamento | |
| BR112017003880A2 (pt) | derivados de poliéteres de n-aril-triciclopirimidina-2-amina macrocíclicos como inibidores de ftl3 e jak |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/08/2015, OBSERVADAS AS CONDICOES LEGAIS |